A carregar...
Long-term Remission Over Six Years for a Patient with Recurrent Glioblastoma Treated with Cediranib/Lomustine
Cediranib is an orally available, pan-VEGFR tyrosine kinase inhibitor. A previous Phase III study of patients with recurrent glioblastoma treated with this drug did not meet the primary end of progressive-free survival (PFS). We identified one patient, a 57-year-old Caucasian female who, following s...
Na minha lista:
| Publicado no: | Cureus |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Cureus
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4757029/ https://ncbi.nlm.nih.gov/pubmed/26929887 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7759/cureus.460 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|